Verastem, Inc. (NASDAQ:VSTM), focused on developing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 30(th) Annual ROTH Conference on Monday, March 12, 2018 at 4:30 pm PST in Dana Point, CA, USA.
After about four months on the positive results for their main top line (Duvelisib ) , which was announced at Dec last year, many investors are still waiting for a real change in the share price of the company. Even after the announcement of submitting the new drug application The price of the stock was not much affected by this news and remained less than expected to be.
So Does this mean it is the end of the story for VSTM? The answer is of course not. The opportunity of their drug to get approval and to be licensed is still in good shape. However, there is no real guarantee for this to happen. The company still has an optimistic view from an excellent number of analysts.
With all respect, we believe there is still a bright future waiting for this company. We like to say this stock now stands on stable hold /Buy rate; a possible good entry is between 3.05 up to 3.32. Our price target for the next 20 days is 3.90.
Important note : We are just a small team of independent traders and uncertified technical chart analysis, and we do not have any insider trading or connection with any company related to any stocks we mentioned. You own your decision to buy, hold or sell any of them. Pay attention : If you would like to receive our last awesome picks for a day, swing and long trade, please subscribe to our mailing list .
Share on Facebook
Share on Twitter
I'm busy working on my blog posts. Watch this space!